Navigation Links
For Multiple Sclerosis Treatment, Prescriber Base for Genzyme's Aubagio Among U.S. Neurologists Has Increased Significantly at Six Months Post-launch, Compared to One and Three Months Post-launch
Date:5/30/2013

EXTON, Pa., May 30, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that over half of surveyed neurologists have prescribed Aubagio, the second oral disease-modifying agent (DMA) marketed for multiple sclerosis (MS), to at least one of their MS patients at six months post-launch. While this represents a significant increase in prescriber base from one and three months post-launch, it does trail that observed with Gilenya (according to LaunchTrends: Gilenya Wave 3) at the same stage of product launch. This difference in prescriber base between the two oral DMAs is reflected in a smaller Aubagio patient share among DMA-treated relapsing-remitting MS (RR-MS) patients compared with the six-month share reported for Gilenya. Nevertheless, initial uptake of Aubagio continues to be driven by the product's convenient once-daily, oral formulation, with the majority of patients initiated on Aubagio still coming from switches.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

With Biogen Idec's Tecfidera being approved days before current survey fielding, substantial press coverage was given to the comparative wholesale prices across the DMAs, with Aubagio being the least expensive. Data from the LaunchTrends: Aubagio Wave 3 report suggest that this information has not had the expected impact on neurologists' perceptions of Aubagio's cost as significantly more of the 73 surveyed neurologists now perceive Aubagio as being more expensive than the other DMAs compared with previous waves. Furthermore, while current prescribers continue to express high overall satisfaction with Aubagio, especially for its efficacy, they rate their satisfaction with the product's cost significantly lower than at three months post-launch. Qualitative feedback suggests that difficulties with managed care coverage of Aubagio may be having a trickle-down effect on neurologists' perception of Aubagio's price.

"Given that neurologists report currently treating 9 percent of their DMA-treated RR-MS patients with the oral DMAs available at the time of survey fielding (Aubagio and Gilenya), it is interesting to note that surveyed neurologists expect the oral DMA group to capture 23 percent patient share over the next six months," said BioTrends Research Group Analyst Emma Williams , Ph.D. "Although this growth is anticipated to be driven predominantly by Tecfidera uptake, Aubagio patient share is also projected to significantly increase, while Gilenya patient share is expected to remain stable."

Overall, these results highlight neurologists' growing receptivity to oral DMAs and indicate a general shift in the MS treatment algorithm, away from the platform DMAs (Biogen Idec's Avonex, Bayer HealthCare's Betaseron, Teva's Copaxone and Pfizer/EMD Serono's Rebif) and Biogen Idec's Tysabri.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
2. Roskamp Institute Reports Beneficial Effects of Nutritional Supplementation with Anatabine in an Animal Model of Multiple Sclerosis
3. Aushon to Launch New Multiplex Immunoassay Platform
4. Multiple Sclerosis Association of Americas MRI Institute Marks 10 Years of Helping Individuals with Multiple Sclerosis Obtain MRIs
5. Hearing Loss Could Lead to Multiple Chronic Diseases for Millions of Brits
6. Researchers Developing New Multiple Sclerosis Drug That Can Be Taken Orally
7. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
8. Life Technologies Develops Simplified SAME-DAY STEC Solution for Detecting Multiple Strains of E. coli in Ground Beef
9. Therapy Trends: Multiple Sclerosis
10. New International Survey Reveals Multiple Barriers to an Accurate and Timely Alzheimers Disease Diagnosis
11. Eutropics Pharmaceuticals signs $1.5M NCI/SBIR contract to develop companion diagnostic for guiding Multiple Myeloma treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Research and Markets has announced the addition of ... BUN Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic Panel, Liver Panel, ... 2024" report to their offering. ... The global clinical laboratory testing market is ... of innovative solutions on the grounds of maximum efficiency and minimum ...
(Date:1/20/2017)... BUFFALO, N.Y. , Jan. 20, 2017 /PRNewswire/ ... health programs, has announced the launch of an ... to new guidelines on opioids and helps stem ... Opioids are often prescribed to treat chronic non-cancer ... disease) despite serious risks and lack of evidence ...
(Date:1/19/2017)... NEW YORK , Jan. 19, 2017 /PRNewswire/ ... reach USD 233.7 billion by 2025, according to ... The market is anticipated to be predominantly driven ... companies, resulting into the large-scale production of new ... widen the influx of drugs at an unprecedented ...
Breaking Medicine Technology:
(Date:1/21/2017)... , ... January 21, 2017 , ... Seamild, the largest ... the futuristic vision of its owner and founder. As Oat is recognized globally as ... everybody he knows personally as he believes it is a move to sow the ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... of Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for its annual ... alumni, family, friends, and community. “Coming Home 2017” will be held on ...
(Date:1/21/2017)... ... January 21, 2017 , ... Santa Rosa Orthopaedics (SRO) ... located at 167 Lynch Creek Way. The Petaluma office features three comfortable patient ... and rehabilitation services and on-site x-ray services. Two multi-specialist orthopaedic surgeons Dr. ...
(Date:1/21/2017)... ... 2017 , ... The Nobel Biocare™ dental implant company is ... its creos™ line of bone regenerative products. Specifically, the Nobel Biocare™ ... creos™ allo.gain™ bone graft for a variety of bone reconstruction procedures. In addition ...
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between ... they no longer use or need, from clothes to couches to dressers and bicycles. ... and take them to the nearest Goodwill donation center through February 28th. , ...
Breaking Medicine News(10 mins):